<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAFCIT- caffeine citrateÂ injectionÂ </strong><br><strong>CAFCIT- caffeine citrateÂ solutionÂ </strong><br>Bedford Laboratories<br></p></div>
<h1><span class="Bold">CAFCIT (caffeine citrate) Injection and CAFCIT (caffeine citrate) Oral Solution</span></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b913b736-fef5-4e39-9874-4b70c0079218"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx ONLY</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_b706a905-b2df-4522-9491-7666d0d930bd"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Both CAFCITÂ® (caffeine citrate) Injection for intravenous administration and CAFCITÂ® (caffeine citrate) Oral Solution are clear, colorless, sterile, non-pyrogenic, preservative-free, aqueous solutions adjusted to pH 4.7. Each mL contains 20 mg caffeine citrate (equivalent to 10 mg of caffeine base) prepared in solution by the addition of 10 mg caffeine anhydrous to 5.0 mg citric acid monohydrate, 8.3 mg sodium citrate dihydrate and Water for Injection.</p>
<p>Caffeine, a central nervous system stimulant, is an odorless white crystalline powder or granule, with a bitter taste. It is sparingly soluble in water and ethanol at room temperature. The chemical name of caffeine is 3,7-dihydro-1,3,7-trimethyl-1<span class="Italics">H</span>-purine-2,6-dione. In the presence of citric acid it forms caffeine citrate salt in solution. The structural formula and molecular weight of caffeine citrate follows.</p>
<div class="Figure">
<a name="id290"></a><img alt="structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0&amp;name=669eda7d-cd85-42fa-9dac-3c8b76595639-01.jpg">
</div>
<p>Caffeine citrate</p>
<p>C<span class="Sub">14</span>H<span class="Sub">18</span>N<span class="Sub">4</span>O<span class="Sub">9</span> Mol. Wt. 386.31</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_7a7bf403-c166-4b42-a079-31212af30dbc"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_13768d94-93a2-4911-b88c-38b66e5c170a"></a><a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Caffeine is structurally related to other methylxanthines, theophylline, and theobromine. It is a bronchial smooth muscle relaxant, a CNS stimulant, a cardiac muscle stimulant, and a diuretic.</p>
<p>Although the mechanism of action of caffeine in <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> is not known, several mechanisms have been hypothesized. These include: (1) stimulation of the respiratory center, (2) increased minute ventilation, (3) decreased threshold to <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, (4) increased response to <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercapnia</span>, (5) increased skeletal muscle tone, (6) decreased diaphragmatic <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, (7) increased metabolic rate, and (8) increased oxygen consumption.</p>
<p>Most of these effects have been attributed to antagonism of adenosine receptors, both A<span class="Sub">1</span> and A<span class="Sub">2</span> subtypes, by caffeine, which has been demonstrated in receptor binding assays and observed at concentrations approximating those achieved therapeutically.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_3b6215d6-b1f9-42df-ab36-4a050b60f707"></a><a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9010045a-030e-484d-a733-5b5b6cdbd930"></a><a name="section-3.2.1"></a><p></p>
<h3><span class="Bold">Absorption </span></h3>
<p class="First">After oral administration of 10 mg caffeine base/kg to preterm neonates, the peak plasma level (C<span class="Sub">max</span>) for caffeine ranged from 6-10 mg/L and the mean time to reach peak concentration (T<span class="Sub">max</span>) ranged from 30 minutes to 2 hours. The T<span class="Sub">max</span> was not affected by formula feeding. The absolute bioavailability, however, was not fully examined in preterm neonates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_446bec7b-cbce-48ca-bd17-8d206e519492"></a><a name="section-3.2.2"></a><p></p>
<h3><span class="Bold">Distribution </span></h3>
<p class="First">Caffeine is rapidly distributed into the brain. Caffeine levels in the cerebrospinal fluid of preterm neonates approximate their plasma levels. The mean volume of distribution of caffeine in infants (0.8-0.9 L/kg) is slightly higher than that in adults (0.6 L/kg). Plasma protein binding data are not available for neonates or infants. In adults, the mean plasma protein binding in vitro is reported to be approximately 36%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26a3110d-a4bd-4efe-b8fc-48a2f5c09fae"></a><a name="section-3.2.3"></a><p></p>
<h3><span class="Bold">Metabolism </span></h3>
<p class="First">Hepatic cytochrome P450 1A2 (CYP1A2) is involved in caffeine biotransformation. Caffeine metabolism in preterm neonates is limited due to their immature hepatic enzyme systems.</p>
<p>Interconversion between caffeine and theophylline has been reported in preterm neonates; caffeine levels are approximately 25% of theophylline levels after theophylline administration and approximately 3-8% of caffeine administered would be expected to convert to theophylline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3534913b-44f8-4d7b-8cfd-bd419292e3df"></a><a name="section-3.2.4"></a><p></p>
<h3><span class="Bold">Elimination</span></h3>
<p class="First">In young infants, the elimination of caffeine is much slower than that in adults due to immature hepatic and/or renal function. Mean half-life (T<span class="Sub">1/2</span>) and fraction excreted unchanged in urine (A<span class="Sub">e)</span> of caffeine in infants have been shown to be inversely related to gestational/postconceptual age. In neonates, the T<span class="Sub">1/2</span> is approximately 3-4 days and the A<span class="Sub">e</span> is approximately 86% (within 6 days). By 9 months of age, the metabolism of caffeine approximates that seen in adults (T<span class="Sub">1/2</span> = 5 hours and A<span class="Sub">e</span> = 1%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1f02e983-daaa-4c18-acbc-00e99dd85f74"></a><a name="section-3.2.5"></a><p></p>
<h3><span class="Bold">Special Populations</span></h3>
<p class="First">Studies examining the pharmacokinetics of caffeine in neonates with hepatic or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> have not been conducted. CAFCIT (caffeine citrate) should be administered with caution in preterm neonates with impaired renal or hepatic function. Serum concentrations of caffeine should be monitored and dose administration of CAFCIT should be adjusted to avoid toxicity in this population.</p>
<p><span class="Bold">Clinical Studies</span></p>
<p>One multicenter, randomized, double-blind trial compared CAFCIT (caffeine citrate) to placebo in eighty five (85) preterm infants (gestational age 28 to &lt;33 weeks) with <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span>. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> was defined as having at least 6 <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> episodes of greater than 20 seconds duration in a 24-hour period with no other identifiable cause of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. A 1 mL/kg (20 mg/kg caffeine citrate providing 10 mg/kg as caffeine base) loading dose of CAFCIT was administered intravenously, followed by a 0.25 mL/kg (5 mg/kg caffeine citrate providing 2.5 mg/kg of caffeine base) daily maintenance dose administered either intravenously or orally (generally through a feeding tube). The duration of treatment in this study was limited to 10 to 12 days. The protocol allowed infants to be "rescued" with open-label caffeine citrate treatment if their <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> remained uncontrolled during the double-blind phase of the trial.</p>
<p>The percentage of patients without <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> on day 2 of treatment (24-48 hours after the loading dose) was significantly greater with CAFCIT than placebo. The following table summarizes the clinically relevant endpoints evaluated in this study:</p>
<p>Â </p>
<table width="100%">
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold">CAFCIT</span></p></td>
<td class="Botrule Rrule Toprule" align="center"><p class="First"><span class="Bold"> Placebo</span></p></td>
<td class="Botrule Toprule" align="center"><p class="First"><span class="Bold">p-value</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Number of patients evaluated<span class="Sup">1</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">45</p></td>
<td class="Botrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">% of patients with zero <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> events on day 2</p></td>
<td class="Botrule Rrule" align="center"><p class="First">26.7</p></td>
<td class="Botrule Rrule" align="center"><p class="First">8.1</p></td>
<td class="Botrule" align="center"><p class="First">0.03</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> rate on day 2 (per 24 h)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4.9</p></td>
<td class="Botrule Rrule" align="center"><p class="First">7.2 </p></td>
<td class="Botrule" align="center"><p class="First">0.134</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule">
<p class="First">% of patients with 50% reduction in </p>
<p><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> events from baseline on day 2</p>
</td>
<td class="Botrule Rrule" align="center"><p class="First">76</p></td>
<td class="Botrule Rrule" align="center"><p class="First">57</p></td>
<td class="Botrule" align="center"><p class="First">0.07</p></td>
</tr>
</tbody>
</table>
<p><span class="Sup">1</span> Of 85 patients who received drug, 3 were not included in the efficacy analysis because they had &lt;6 <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> episodes/24 hours at baseline.</p>
<p>In this 10-12 day trial, the mean number of days with zero <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> events was 3.0 in the CAFCIT group and 1.2 in the placebo group. The mean number of days with a 50% reduction from baseline in <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> events was 6.8 in the CAFCIT group and 4.6 in the placebo group.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_2cb12ff8-5c5e-4352-9f1b-62b1019205f3"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CAFCIT (caffeine citrate) is indicated for the short-term treatment of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> in infants between 28 and &lt;33 weeks gestational age.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e44414c0-73ac-4318-bbdb-7c1ee30c311a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CAFCIT (caffeine citrate) is contraindicated in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_fa5a99a6-09eb-436c-b971-b61ef9c4b040"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">During the double-blind, placebo-controlled clinical trial, 6 cases of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> developed among the 85 infants studied (caffeine=46, placebo=39), with 3 cases resulting in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Five of the six patients with <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> were randomized to or had been exposed to CAFCIT (caffeine citrate).</p>
<p>Reports in the published literature have raised a question regarding the possible association between the use of methylxanthines and development of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>, although a causal relationship between methylxanthine use and <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> has not been established. Therefore, as with all preterm infants, patients being treated with CAFCIT should be carefully monitored for the development of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_998abb3b-1e33-4ca6-b53e-8f9c05b54240"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_7b972233-447d-40e7-99e8-40def62b0fc9"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> is a diagnosis of exclusion. Other causes of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> (e.g., <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">central nervous system disorders</span>, primary <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, metabolic disturbances, cardiovascular abnormalities, or obstructive <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>) should be ruled out or properly treated prior to initiation of CAFCIT (caffeine citrate).</p>
<p>Caffeine is a central nervous system stimulant and in cases of caffeine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> have been reported. CAFCIT should be used with caution in infants with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders.</p>
<p>The duration of treatment of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> in the placebo-controlled trial was limited to 10 to 12 days. The safety and efficacy of CAFCIT for longer periods of treatment have not been established. Safety and efficacy of CAFCIT for use in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment of <span class="product-label-link" type="condition" conceptid="435937" conceptname="Sudden infant death syndrome">sudden infant death syndrome</span> (<span class="product-label-link" type="condition" conceptid="435937" conceptname="Sudden infant death syndrome">SIDS</span>) or prior to extubation in mechanically ventilated infants have also not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_82ccffe4-0929-4309-a4b7-1eef8009ef94"></a><a name="section-7.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First">Although no cases of cardiac toxicity were reported in the placebo-controlled trial, caffeine has been shown to increase heart rate, left ventricular output, and <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> in published studies. Therefore, CAFCIT should be used with caution in infants with cardiovascular disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_97ee99ef-9bcd-4eda-802e-f873019baa84"></a><a name="section-7.3"></a><p></p>
<h2>Renal and Hepatic Systems</h2>
<p class="First">CAFCIT should be administered with caution in infants with impaired renal or hepatic function. Serum concentrations of caffeine should be monitored and dose administration of CAFCIT should be adjusted to avoid toxicity in this population. (See <span class="Bold"><a href="#i4i_clinical_pharmacology_id_7a7bf403-c166-4b42-a079-31212af30dbc">CLINICAL PHARMACOLOGY</a></span>, <a href="#i4i_section_id_3534913b-44f8-4d7b-8cfd-bd419292e3df">Elimination</a>, <a href="#i4i_section_id_1f02e983-daaa-4c18-acbc-00e99dd85f74">Special Populations</a>.)</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_77aa84a5-3023-497a-99ce-a8c6b22a9f97"></a><a name="section-7.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Parents/caregivers of patients receiving CAFCIT (caffeine citrate) Oral Solution should receive the following instructions:</p>
<p>1. CAFCIT does not contain any preservatives and each vial is for single use only. Any unused portion of the medication should be discarded.</p>
<p>2. It is important that the dose of CAFCIT be measured accurately, i.e., with a 1cc or other appropriate syringe.</p>
<p>3. Consult your physician if the baby continues to have <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> events; do not increase the dose of CAFCIT without medical consultation.</p>
<p>4. Consult your physician if the baby begins to demonstrate signs of gastrointestinal intolerance, such as abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span>, or seems <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargic</span>.</p>
<p>5. CAFCIT should be inspected visually for particulate matter and discoloration prior to its administration. Vials containing discolored solution or visible particulate matter should be discarded.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_a74c5ea8-bae8-46b7-801a-97b5a1a68eee"></a><a name="section-7.5"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Prior to initiation of CAFCIT (caffeine citrate), baseline serum levels of caffeine should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to caffeine. Likewise, baseline serum levels of caffeine should be measured in infants born to mothers who consumed caffeine prior to delivery, since caffeine readily crosses the placenta.</p>
<p>In the placebo-controlled clinical trial, caffeine levels ranged from 8 to 40 mg/L. A therapeutic plasma concentration range of caffeine could not be determined from the placebo-controlled clinical trial. Serious toxicity has been reported in the literature when serum caffeine levels exceed 50 mg/L. Serum concentrations of caffeine may need to be monitored periodically throughout treatment to avoid toxicity.</p>
<p>In clinical studies reported in the literature, cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been observed. Therefore, serum glucose may need to be periodically monitored in infants receiving CAFCIT.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_0961df8f-be21-49fd-ab56-633faccafc9e"></a><a name="section-7.5.1"></a><p></p>
<h3><span class="Bold">Drug Interactions</span></h3>
<p class="First">Cytochrome P450 1A2 (CYP1A2) is known to be the major enzyme involved in the metabolism of caffeine. Therefore, caffeine has the potential to interact with drugs that are substrates for CYP1A2, inhibit CYP1A2, or induce CYP1A2.</p>
<p>Few data exist on drug interactions with caffeine in preterm neonates. Based on adult data, lower doses of caffeine may be needed following coadministration of drugs which are reported to decrease caffeine elimination (e.g., cimetidine and ketoconazole) and higher caffeine doses may be needed following coadministration of drugs that increase caffeine elimination (e.g., phenobarbital and phenytoin).</p>
<p>Caffeine administered concurrently with ketoprofen reduced the urine volume in four healthy volunteers. The clinical significance of this interaction in preterm neonates is not known.</p>
<p>Interconversion between caffeine and theophylline has been reported in preterm neonates. The concurrent use of these drugs is not recommended.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_9e7eec0b-29f8-48e7-b65c-1b6b2320f73d"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a 2-year study in Sprague-Dawley rats, caffeine (as caffeine base) administered in drinking water was not carcinogenic in male rats at doses up to 102 mg/kg or in female rats at doses up to 170 mg/kg (approximately 2 and 4 times, respectively, the maximum recommended intravenous loading dose for infants on a mg/m<span class="Sup">2</span> basis). In an 18-month study in C57BL/6 mice, no evidence of tumorigenicity was seen at dietary doses up to 55 mg/kg (less than the maximum recommended intravenous loading dose for infants on a mg/m<span class="Sup">2</span> basis).</p>
<p>Caffeine (as caffeine base) increased the sister chromatid exchange (SCE) SCE/cell metaphase (exposure time dependent) in an in vivo mouse metaphase analysis. Caffeine also potentiated the genotoxicity of known mutagens and enhanced the micronuclei formation (5-fold) in folate-deficient mice. However, caffeine did not increase chromosomal aberrations in <span class="Italics">in vitro</span> Chinese hamster ovary cell (CHO) and human lymphocyte assays and was not mutagenic in an in vitro CHO/hypoxanthine guanine phosphoribosyltransferase (HGPRT) gene mutation assay, except at cytotoxic concentrations. In addition, caffeine was not clastogenic in an <span class="Italics">in vivo</span> mouse micronucleus assay.</p>
<p>Caffeine (as caffeine base) administered to male rats at 50 mg/kg/day subcutaneously (approximately equal to the maximum recommended intravenous loading dose for infants on a mg/m2 basis) for 4 days prior to mating with untreated females, caused decreased male reproductive performance in addition to causing embryotoxicity. In addition, long-term exposure to high oral doses of caffeine (3.0 g over 7 weeks) was toxic to rat testes as manifested by spermatogenic cell degeneration.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_c298e39d-0b82-42ce-b42b-6df53f689ba4"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab6e79eb-0f5c-443f-9582-6e18633ec8c2"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category C</span></h3>
<p class="First">Concern for the <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> of caffeine is not relevant when administered to infants. In studies performed in adult animals, caffeine (as caffeine base) administered to pregnant mice as sustained release pellets at 50 mg/kg (less than the maximum recommended intravenous loading dose for infants on a mg/m<span class="Sup">2</span> basis), during the period of organogenesis, caused a low incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span> in the fetuses. There are no adequate and well-controlled studies in pregnant women.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_0553428d-521a-4207-b077-a9f5f768a72a"></a><a name="section-7.7.2"></a><p></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_79b4c5e7-d17c-48e5-99ae-db528549240a"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Overall, the reported number of adverse events in the double-blind period of the controlled trial was similar for the CAFCIT (caffeine citrate) and placebo groups. The following table shows adverse events that occurred in the double-blind period of the controlled trial and that were more frequent in CAFCIT-treated patients than placebo.</p>
<a name="_Refid_7583fc97-dc8d-469f-aaf4-391f2a404"></a><table width="100%">
<caption><span>ADVERSE EVENTS THAT OCCURRED MORE FREQUENTLY IN CAFCIT-TREATED PATIENTS THAN PLACEBO DURING DOUBLE-BLIND THERAPY</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First">Adverse Event (AE) </p></td>
<td class="Botrule Rrule Toprule" align="center">
<p class="First">CAFCIT N=46 </p>
<p>n (%)</p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First">Placebo N=39 </p>
<p>n (%)</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">BODY AS A WHOLE</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Feeding Intolerance</p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (8.7)</p></td>
<td class="Botrule" align="center"><p class="First">2 (5.1)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4.3)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">CARDIOVASCULAR SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">DIGESTIVE SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">Necrotizing Enterocolitis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">2 (4.3)</p></td>
<td class="Botrule" align="center"><p class="First">1 (2.6)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal Hemorrhage</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">HEMIC AND LYMPHATIC SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">Disseminated Intravascular Coagulation</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">METABOLIC AND NUTRITIVE DISORDERS</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acidosis</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4304198" conceptname="Impaired tissue repair">Healing Abnormal</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">NERVOUS SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">Cerebral Hemorrhage</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">RESPIRATORY SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Lung Edema</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">SKIN AND APPENDAGES</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry Skin</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">4 (8.7)</p></td>
<td class="Botrule" align="center"><p class="First">3 (7.7)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin Breakdown</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">SPECIAL SENSES</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="373766" conceptname="Retinopathy of prematurity">Retinopathy of Prematurity</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">UROGENITAL SYSTEM</p></td>
<td class="Botrule Rrule"></td>
<td class="Botrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Kidney Failure</span></p></td>
<td class="Botrule Rrule" align="center"><p class="First">1 (2.2)</p></td>
<td class="Botrule" align="center"><p class="First">0 (0.0)</p></td>
</tr>
</tbody>
</table>
<p>In addition to the cases above, three cases of <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> were diagnosed in patients receiving CAFCIT (caffeine citrate) during the open-label phase of the study.</p>
<p>Three of the infants who developed <span class="product-label-link" type="condition" conceptid="201957" conceptname="Necrotizing enterocolitis in fetus OR newborn">necrotizing enterocolitis</span> during the trial died. All had been exposed to caffeine. Two were randomized to caffeine, and one placebo patient was â€œrescuedâ€? with open-label caffeine for uncontrolled <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>.</p>
<p>Adverse events described in the published literature include: central nervous system stimulation (ie, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>), cardiovascular effects (ie, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, increased left ventricular output, and increased <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span>), gastrointestinal effects (ie, increased gastric aspirate, gastrointestinal intolerance), alterations in serum glucose (ie, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>), and renal effects (ie, increased urine flow rate, increased creatinine clearance, and increased sodium and calcium excretion). Published long-term follow-up studies have not shown caffeine to adversely affect neurological development or growth parameters.</p>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_4df7900b-9fc6-4a63-b314-1f020bf12fda"></a><a name="section-8.1"></a><p></p>
<h2>OVERDOSAGE</h2>
<p class="First">Following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, serum caffeine levels have ranged from approximately 24 mg/L (a postmarketing spontaneous case report in which an infant exhibited <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, poor feeding, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>) to 350 mg/L. Serious toxicity has been associated with serum levels greater than 50 mg/L (see <span class="Bold"><a href="#i4i_precautions_id_998abb3b-1e33-4ca6-b53e-8f9c05b54240">PRECAUTIONS</a> â€“ <a href="#i4i_lab_tests_id_a74c5ea8-bae8-46b7-801a-97b5a1a68eee">Laboratory tests</a></span>and <span class="Bold"><a href="#i4i_dosage_admin_id_04243e52-92ad-415a-acf4-943a8ebc165a">DOSAGE AND ADMINISTRATION</a></span>). Signs and symptoms reported in the literature after caffeine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in preterm infants include <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, fine <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> of the extremities, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4313849" conceptname="Opisthotonus">opisthotonos</span>, tonic-<span class="product-label-link" type="condition" conceptid="4270553" conceptname="Clonus">clonic movements</span>, nonpurposeful jaw and lip movements, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, elevated blood urea nitrogen, and elevated total leukocyte concentration. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have also been reported in cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. One case of caffeine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> complicated by development of <span class="product-label-link" type="condition" conceptid="443752" conceptname="Ventricular hemorrhage">intraventricular hemorrhage</span> and long-term neurological sequelae has been reported. Another case of caffeine citrate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (from New Zealand; not CAFCIT) of an estimated 600 mg caffeine citrate (approximately 322 mg/kg) administered over 40 minutes was complicated by <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, ST <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, gastric <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, and a severe <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> burn with tissue <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> at the peripheral intravenous injection site. No <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> associated with caffeine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been reported in preterm infants.</p>
<p>Treatment of caffeine <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is primarily symptomatic and supportive. Caffeine levels have been shown to decrease after exchange transfusions. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> may be treated with intravenous administration of diazepam or a barbiturate such as pentobarbital sodium.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_04243e52-92ad-415a-acf4-943a8ebc165a"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Prior to initiation of CAFCIT (caffeine citrate), baseline serum levels of caffeine should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to caffeine. Likewise, baseline serum levels of caffeine should be measured in infants born to mothers who consumed caffeine prior to delivery, since caffeine readily crosses the placenta.</p>
<p>The recommended loading dose and maintenance doses of CAFCIT follow.</p>
<table width="100%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Rrule Toprule"><p class="First">Dose of CAFCIT (caffeine citrate) Volume</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Dose of CAFCIT (caffeine citrate) mg/kg</p></td>
<td class="Botrule Rrule Toprule"><p class="First">Route</p></td>
<td class="Botrule Toprule"><p class="First">Frequency</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Loading Dose</p></td>
<td class="Botrule Rrule"><p class="First">1 mL/kg</p></td>
<td class="Botrule Rrule"><p class="First">20 mg/kg</p></td>
<td class="Botrule Rrule"><p class="First">Intravenous* (over 30 minutes)</p></td>
<td class="Botrule"><p class="First">One Time</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Maintenance Dose</p></td>
<td class="Botrule Rrule"><p class="First">0.25 mL/kg</p></td>
<td class="Botrule Rrule"><p class="First">5 mg/kg</p></td>
<td class="Botrule Rrule">
<p class="First">Intravenous* </p>
<p> (over 10 minutes) or Orally</p>
</td>
<td class="Botrule"><p class="First">Every 24 hours**</p></td>
</tr>
</tbody>
</table>
<p>*using a syringe infusion pump</p>
<p>**beginning 24 hours after the loading dose</p>
<p>NOTE THAT THE DOSE OF CAFFEINE BASE IS ONE-HALF THE DOSE WHEN EXPRESSED AS CAFFEINE CITRATE (e.g., 20 mg of caffeine citrate is equivalent to 10 mg of caffeine base).</p>
<p>Serum concentrations of caffeine may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.</p>
<p>CAFCIT should be inspected visually for particulate matter and discoloration prior to administration. Vials containing discolored solution or visible particulate matter should be discarded.</p>
<p><span class="Bold">Drug Compatibility</span></p>
<p>To test for drug compatibility with common intravenous solutions or medications, 20 mL of CAFCIT (caffeine citrate) Injection were combined with 20 mL of a solution or medication, with the exception of an IntralipidÂ® admixture, which was combined as 80 mL/80 mL. The physical appearance of the combined solutions was evaluated for precipitation. The admixtures were mixed for 10 minutes and then assayed for caffeine. The admixtures were then continually mixed for 24 hours, with further sampling for caffeine assays at 2, 4, 8, and 24 hours.</p>
<p>Based on this testing, CAFCIT (caffeine citrate) Injection, 60 mg/3 mL is chemically stable for 24 hours at room temperature when combined with the following test products.</p>
<p>â€¢ Dextrose Injection, USP 5%</p>
<p>â€¢ 50% Dextrose Injection USP</p>
<p>â€¢ IntralipidÂ® 20% IV Fat Emulsion</p>
<p>â€¢ AminosynÂ® 8.5% Crystalline Amino Acid Solution</p>
<p>â€¢ Dopamine HCI Injection, USP 40 mg/mL diluted to 0.6 mg/mL with Dextrose Injection, USP 5% â€¢ Calcium Gluconate Injection, USP 10% (0.465 mEq/Ca<span class="Sup">+2</span>/mL)</p>
<p>â€¢ Heparin Sodium Injection, USP 1000 units/mL diluted to 1 unit/mL with Dextrose Injection, USP 5%</p>
<p>â€¢ Fentanyl Citrate Injection, USP 50 Î¼g/mL diluted to 10 Î¼g/mL with Dextrose Injection, USP 5%</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_5ebff39f-f115-4c4f-ab0c-041804f387dc"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Both CAFCIT (caffeine citrate) Injection and CAFCIT Oral Solution are available as clear, colorless, sterile, non-pyrogenic, preservative-free, aqueous solutions in 3 mL colorless glass vials. The vials of CAFCIT Injection are sealed with a teflon-faced gray rubber stopper and an aluminum overseal with a white flip-off polypropylene disk inset. The vials of CAFCIT Oral Solution are sealed with a teflon-faced gray rubber stopper and a peel-off aluminum overseal with a blue flip-off polypropylene disk inset.</p>
<p>Both the injection and oral solution vials contain 3 mL solution at a concentration of 20 mg/mL caffeine citrate (60 mg/vial) equivalent to 10 mg/mL caffeine base (30 mg/vial).</p>
<p><span class="Bold">CAFCITÂ® (caffeine citrate) Injection</span></p>
<p>NDC 55390-357-03: 3 mL vial, individually packaged in a carton.</p>
<p><span class="Bold">CAFCITÂ® (caffeine citrate) Oral Solution</span></p>
<p>NDC 55390-358-03: 3 mL vial (NOT CHILD-RESISTANT),</p>
<p>10 vials per white polypropylene child-resistant container.</p>
<p>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
<p><span class="Bold">Preservative free. For single use only. Discard unused portion.</span></p>
<p>ATTENTION PHARMACIST: Detach "Instructions for Use" from the package insert and dispense with CAFCIT (caffeine citrate) Oral Solution prescription.</p>
<p>Manufactured by: Ben Venue Laboratories, Inc., Bedford, OH 44146</p>
<p>Manufactured for: Bedford Laboratoriesâ„¢, Bedford, OH 44146</p>
<p>March 2013</p>
<p>CFCO-P02</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_bdab3ac3-0c76-4e91-b90a-d9b5545c1e3a"></a><a name="section-11"></a><p></p>
<h1>CAFCITÂ® (caffeine citrate) Oral Solution</h1>
<p class="First"><span class="Bold">Rx ONLY</span></p>
<p>Each bottle (vial) of CAFCITÂ® contains a total of 60 mg of caffeine citrate in 3 mL (20 mg/mL).</p>
<p><span class="Bold">Information and Instructions for Use</span></p>
<p>This leaflet tells you about CAFClT (KAF-sit) and how to give it to your baby. Read the following information before giving this medicine to your baby. Completely discuss CAFCIT with your babyâ€™s doctor. Continue to discuss any questions you have about this medicine at your babyâ€™s checkups.</p>
<p><span class="Bold">After you remove your babyâ€™s dose, throw away the open bottle (vial) and all medicine leftin it. </span>Use each vial of CAFCIT for only one dose. There will be extra medicine left in the vial after one dose is removed. Leftover medicine should not be used because CAFCIT does not contain preservatives. Once the vial is open, any medicine that is not used right away must be discarded.</p>
<p><span class="Bold">What is CAFCIT?</span></p>
<p>The main ingredient of CAFCIT is caffeine citrate. CAFCIT is a clear, colorless, medicine to treat <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> of prematurityâ€”short periods when premature babies stop breathing. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> of <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">prematurity</span> is due to the babyâ€™s breathing centers not being fully developed.</p>
<p><span class="Bold">How do I give CAFCIT to my baby?</span></p>
<p>Give CAFCIT to your baby once a day, at about the same time each day. Your babyâ€™s doctor will prescribe the right amount of CAFCIT based on your babyâ€™s weight and age. Carefully follow the doctorâ€™s dosing instructions.</p>
<p>Measure the dose of CAFCIT carefully. Your babyâ€™s doctor, nurse, or pharmacist will give you a suitable syringe or supply of syringes to measure small but accurate doses of CAFCIT.</p>
<p>Never change (increase or decrease) your babyâ€™s dose without speaking to your babyâ€™s doctor.</p>
<p><span class="Bold">If your baby continues to have periods of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, call your babyâ€™s doctor right away.</span></p>
<p>CAFCIT can be swallowed by mouth or given through a feeding tube. Based on your babyâ€™s own situation, your babyâ€™s doctor or other healthcare professional should teach you how to give CAFCIT correctly.</p>
<p>CAFCIT should be clear and colorless. Before giving CAFCIT, look for small particles, cloudiness, or discoloration in the medicine. <span class="Bold">Do not use vials that contain cloudy or discolored medicine, orany visible particles.</span></p>
<p>CAFCIT does <span class="Bold">NOT </span>contain any preservatives. Do not open the vial until it is time for your baby to receive the dose of medicine. Use each vial only once. After you remove your babyâ€™s dose, throw away the vial and all medicine left in the opened vial.</p>
<p>Ten (10) vials of CAFCIT are packaged in a child-resistant container. CAFClT vials are <span class="Bold">NOT CHILD-RESISTANT. </span>Always store vials of CAFCIT in the child-resistant container. Follow the instructions below to open the child-resistant container, to open a vial of CAFCIT, and to remove a dose of medicine from the vial.</p>
<p><span class="Bold">To open the child-resistant container that holds the vials of CAFCIT:</span></p>
<p>(Instructions with pictures are also printed on the top of the container.)</p>
<p>1. Hold the bottom half of the child-resistant container with one hand and push the lower semicircular section on the front of the container with your thumb.</p>
<p>2. With your other hand, pull the cover up until you hear it click.</p>
<p>3. While holding the ends of the bottom half of the container with both hands, place both index fingers on the two semicircular locking tabs on the sides of the container.</p>
<p>4. Press the two tabs and raise the cover up.</p>
<p><span class="Bold">To open a vial of CAFCIT:</span></p>
<p>1. Hold the blue plastic top between the thumb and index finger. Use your thumb to flip the blue plastic top completely off the vial.</p>
<p>2. Carefully lift up the metal ring.</p>
<p>3. Pull the metal ring away from the vial and then pull it down towards the bottom of the vial without twisting the ring.</p>
<p>4. After you pull the ring down and the metal band around the top of the vial is completely broken through, carefully remove the rest of the metal band by pulling it out and away from the vial.</p>
<p>5. Being careful not to spill any medicine, remove the rubber stopper from the top of the vial.</p>
<p><span class="Bold">To remove the prescribed dose from the vial:</span></p>
<p>You will need a small syringe to measure the exact amount of medicine that your babyâ€™s doctor prescribed. Your babyâ€™s doctor, nurse or pharmacist will give you this small syringe. <span class="Bold">Note that a milliliter (mL) is the same as a cubic centimeter (cc).</span></p>
<p>1. Insert the tip of the syringe in the medicine and pull up on the plunger to draw the medicine into the syringe. Remove slightly more of the medicine than the exact amount to be given to your baby.</p>
<p>2. Turn the syringe tip up so that any air in it rises to the top. Remove the air by gently pushing up on the syringe plunger. Continue to push the syringe plunger up to remove any extra medicine in the syringe, until only the exact number of milliliters (or cubic centimeters) that your babyâ€™s doctor prescribed remains in the syringe.</p>
<p>3. Give the CAFCIT to your baby as your babyâ€™s doctor instructed.</p>
<p>4. Throw away the sharp metal pieces, the rubber stopper, the open vial, and any medicine that remains in it after your baby receives the dose.</p>
<p><span class="Bold">What are possible side effects of CAFCIT?</span></p>
<p>Your baby may or may not develop side effects from taking CAFCIT. Each baby is different. If your baby develops one or more of the following symptoms, speak with your babyâ€™s doctor right away:</p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">jitteriness</span>, or <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span></p>
<p>â€¢ faster heart beat</p>
<p>â€¢ increased urination (increased diaper wetting)</p>
<p><span class="Bold">The following symptoms may be caused by serious bowel or stomach problems. Call your babyâ€™s doctor right away if your baby develops:</span></p>
<p>â€¢ bloated abdomen (stomach area)</p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (bloody bowel movements)</p>
<p>â€¢ <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">loss of energy</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (acting sluggish)</p>
<p>This is not a complete list of side effects reported with CAFCIT. If you have a concern about your baby, speak with your babyâ€™s doctor. If you want more information about CAFCIT, speak with your babyâ€™s doctor or pharmacist.</p>
<p>Manufactured for: </p>
<p>Bedford Laboratoriesâ„¢</p>
<p> Bedford, OH 44146</p>
<p>CFCO-P02</p>
<p>March 2013</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_4bc04f7b-b8dc-4f05-8923-9a180159c232"></a><a name="section-12"></a><p></p>
<h1>VIAL LABEL (Injection)</h1>
<div class="Figure">
<a name="id864"></a><img alt="Vial label for Cafcit Injection" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0&amp;name=669eda7d-cd85-42fa-9dac-3c8b76595639-02.jpg"><p class="MultiMediaCaption">Vial Label (Injection) 60 mg/3 mL </p>
</div>
<p class="First">Vial Label (Injection) 60 mg/3 mL </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_5f4910e8-7b63-43c7-8d8c-08e3f3a3f068"></a><a name="section-13"></a><p></p>
<h1>VIAL LABEL (Oral Solution)</h1>
<div class="Figure">
<a name="id878"></a><img alt="Vial label for Cafcit Oral Solution" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0&amp;name=669eda7d-cd85-42fa-9dac-3c8b76595639-03.jpg"><p class="MultiMediaCaption">Vial Label (Oral Solution) 60 mg/3 mL </p>
</div>
<p class="First">Vial Label (Oral Solution) 60 mg/3 mL </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAFCITÂ 		
					</strong><br><span class="contentTableReg">caffeine citrate injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55390-357</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAFFEINE CITRATE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE CITRATE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">8.3Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55390-357-03</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020793</td>
<td class="formItem">11/04/2008</td>
<td class="formItem">04/30/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAFCITÂ 		
					</strong><br><span class="contentTableReg">caffeine citrate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55390-358</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CAFFEINE CITRATE</strong> (CAFFEINE) </td>
<td class="formItem">CAFFEINE CITRATE</td>
<td class="formItem">20Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">5Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">8.3Â mg Â inÂ 1Â mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55390-358-03</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020793</td>
<td class="formItem">11/04/2008</td>
<td class="formItem">05/29/2016</td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Bedford Laboratories
							(884528407)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>be5e4f4b-51a8-40e5-989f-5655667d9bbd</div>
<div>Set id: fbcd234e-57e1-4da2-a96c-e3f7b7cf6ec0</div>
<div>Version: 4</div>
<div>Effective Time: 20140527</div>
</div>
</div>Â <div class="DistributorName">Bedford Laboratories</div></p>
</body></html>
